Actuate Therapeutics Inc
ACTU
NASDAQ·Healthcare·Biotechnology·Mkt cap $35.4M
$1.48
▲ +8.03%
P/E
-1.66
Mkt Cap
$35.4M
52-Wk Range
$0.90–$8.55
52-Week Range
$0.90 - $8.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 81.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel glycogen synthase kinase-3 inhibitor technology
- Focused clinical-stage oncology pipeline
- Targeted therapeutic approach
- Specialized research team
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Advancing clinical trials
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-18.7% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ACTU right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$0.20 vs -$0.21 consensus (+4.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Rodman & Renshaw · Jul 30, 2026
vs Industry
How ACTU stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related